



中华临床医师杂志 (电子版)

Chinese Journal of Clinicians (Electronic Edition)

登

[首页](#) [最新一期](#) [期刊动态](#) [过刊浏览](#) [医学视频](#) [在线投稿](#) [期刊检索](#) [期刊订阅](#) [合作科室](#)

期刊导读

8卷5期 2014年3月 [最新]

期刊存档

期刊存档

[查看目录](#)

期刊订阅

在线订阅

邮件订阅

RSS

作者中心

资质及晋升信息

作者查稿

写作技巧

投稿方式

作者指南



期刊服务

建议我们

会员服务

广告合作

继续教育

您的位置: [首页](#)>> 文章摘要[中文](#)[English](#)

Meta分析对肾去交感神经术治疗顽固性高血压试验的再评价

段慧楠，张丹，王晞，党松

430060 武汉大学人民医院心内科（段慧楠、王晞、党松）；武汉市第五医院心内科（张丹）

王晞，Email: wangxiwhu@163.com

摘要:目的 利用Meta分析方法可合并同质研究提高检验效能的特点, 对肾去交感神经术治疗顽固性高血压试验的再评价。方法 对纳入的Symplicity HNT-1、Symplicity HNT-1补充、Symplicity HNT-2和Symplicity RSD临床随机对照试验, 依据GRADE系统推荐分级方法, 进行质量评价, 运用Review Manager对试验结果进行再评价。结果 Meta分析的两个终点的结果显示: 肾去交感神经术治疗优于单纯药物治疗, 其差异具有统计学意义(95%CI)分别为14.83(6.63, 32.20)、3.45(1.18, 10.08)。GRADE系统推荐分级显示: 以术后降压药物治疗为事件终点, 四项试验证据等级均为低级; 以术后6个月患者收缩压血压值为终点, Symplicity HNT-1和Symplicity RSD试验证据等级为中级, Symplicity HNT-1补充试验、Symplicity HNT-2试验证据等级为低级。结论 降低10 mm Hg为疗效标准, 肾去交感神经术治疗顽固性高血压优于单纯药物治疗, 且无严重并发症。但纳入的研究少、样本含量低, 仍需开展大样本、多中心、科学规范的临床随机对照试验, 以全面评价肾去交感神经术治疗顽固性高血压的有效性。

关键词:肾高血压; Meta分析; 随机对照试验; 去交感神经术

[评论](#) [收藏](#) [全](#)

文献标引:段慧楠，张丹，王晞，党松. Meta分析对肾去交感神经术治疗顽固性高血压试验的再评价[J/CD]. 中华临床医师杂志(电子版), 2013, 7(23):10819-10824. [复制](#)

参考文献:

- [1] Kearney PM, Whelton M, Reynolds K. Global burden of hypertension: analysis of worldwide data. Lancet, 2005, 365: 217-223.
- [2] Schmidendorf RE, Rondon J, Grassi G, et al. ESH Position Paper: renal denervation for resistant hypertension. J Hypertens, 2012, 30: 837-841.
- [3] Krum H, Schlaich M, Whitbourn R. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet, 2009, 374: 1039-1046.
- [4] Symplicity HTN-1 Investigators 2011. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension, 2011, 57: 101-107.
- [5] Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with resistant hypertension: results from the randomized controlled Symplicity HTN-2 trial. J Am Med Assoc, 2012, 307: 1013-1021.

- [6] Ukena C, Mahfoud F, Kindermann I, et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. *J Am Coll Cardiol*, 2012, 59: 1903–1909.
- [7] Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. *Hypertension*, 2012, 59: 419–424.
- [8] Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. *BMJ*, 2004, 328: 1490.
- [9] Smithwick RH. Hypertensive vascular disease; results of and indications for renal sympathectomy. *Am J Med*, 1955, 16: 477–496.
- [10] Di Daniele N, De Francesco M, Violo L, et al. Renal sympathetic nerve ablation for treatment of difficult-to-control or refractory hypertension in a haemodialysis patient. *Transplantation*, 2012, 93: 1689–1690.
- [11] Voskuil M, Verloop WL, Blankestijn PJ, et al. Percutaneous renal denervation for resistant essential hypertension; the first Dutch experience. *Neth Heart J*, 2011, 19: 260–264.
- [12] Damascelli B, Patelli G, Tichá V, et al. Catheter-based radiofrequency renal denervation for resistant hypertension. *J Vasc Interv Radiol*, 2013, 24: 632–639.
- [13] Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. *Circulation*, 2013, 127: 1870–1877.
- [14] Grassi G, Bertoli S, Seravalle G. Sympathetic nervous system: role in hypertension and chronic kidney disease. *Curr Opin Nephrol Hypertens*, 2012, 21: 46–51.
- [15] Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. *Hypertension*, 2011, 58: 559–565.
- [16] Davies JE, Manisty CH, Petraco R, et al. First-in-man safety evaluation of renal sympathetic denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. *Int J Cardiol*, 2012, 158: 189–192.
- [17] Ahmed H, Miller MA, Dukkipati SR, et al. Adjunctive renal sympathetic denervation for resistant hypertension as upstream therapy in the treatment of atrial fibrillation (H-FIB) study: background and study design. *J Cardiovasc Electrophysiol*, 2013, 24: 503–509.
- [18] Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. *Clin Cardiol*, 2012, 35: 189–195.

2013;7(23):10809-10813.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

完全腹腔镜与腹腔镜远端胃癌根治术疗效的Meta分析

于晓天，蒋超，张楷，张淼，沈正海，张云. . 中华临床医师杂志：电子版
2013;7(23):10814-10818.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

Meta分析对肾去交感神经术治疗顽固性高血压试验的再评价

段慧楠，张丹，王晞，党松. . 中华临床医师杂志：电子版
2013;7(23):10819-10824.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

精氨酸强化肠外营养对结直肠癌患者免疫功能影响的Meta分析

杨薏帆，金启成，闫涵，俞静，曹邦伟. . 中华临床医师杂志：电子版
2013;7(23):10825-10830.

[摘要](#) [FullText](#) [PDF](#) [评论](#) [收藏](#)

| 编委会 | 联系我们 | 合作伙伴 | 友情链接 |

© 2014版权声明 中华临床医师杂志(电子版)编辑部
网站建设：北京华夏世通信息技术有限公司 京ICP备0
北京市公安局西城分局备案编号：110102000676